- Home
- EHC vs BMRN Comparison
EHC vs BMRN Comparison
Compare EHC & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHC
- BMRN
- Stock Information
- Founded
- EHC 1983
- BMRN 1996
- Country
- EHC United States
- BMRN United States
- Employees
- EHC N/A
- BMRN N/A
- Industry
- EHC Hospital/Nursing Management
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- EHC Health Care
- BMRN Health Care
- Exchange
- EHC Nasdaq
- BMRN Nasdaq
- Market Cap
- EHC 12.4B
- BMRN 10.0B
- IPO Year
- EHC 1986
- BMRN 1999
- Fundamental
- Price
- EHC $113.85
- BMRN $53.57
- Analyst Decision
- EHC Strong Buy
- BMRN Buy
- Analyst Count
- EHC 8
- BMRN 18
- Target Price
- EHC $141.88
- BMRN $91.06
- AVG Volume (30 Days)
- EHC 768.3K
- BMRN 2.7M
- Earning Date
- EHC 10-29-2025
- BMRN 10-27-2025
- Dividend Yield
- EHC 0.65%
- BMRN N/A
- EPS Growth
- EHC 27.87
- BMRN 59.53
- EPS
- EHC 5.29
- BMRN 2.68
- Revenue
- EHC $5,795,600,000.00
- BMRN $3,094,001,000.00
- Revenue This Year
- EHC $11.57
- BMRN $13.35
- Revenue Next Year
- EHC $8.79
- BMRN $9.18
- P/E Ratio
- EHC $22.07
- BMRN $19.36
- Revenue Growth
- EHC 11.13
- BMRN 12.39
- 52 Week Low
- EHC $87.85
- BMRN $51.10
- 52 Week High
- EHC $127.99
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- EHC 28.34
- BMRN 39.51
- Support Level
- EHC $107.52
- BMRN $52.26
- Resistance Level
- EHC $127.64
- BMRN $56.80
- Average True Range (ATR)
- EHC 3.13
- BMRN 1.66
- MACD
- EHC -0.96
- BMRN -0.10
- Stochastic Oscillator
- EHC 37.57
- BMRN 12.23
About EHC Encompass Health Corporation
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.